This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing ESMO 2022 poster titled "Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration-resistant prostate cancer (mCRPC): initial results from SPLASH"
Ticker(s): PNTWho's the expert?
Institution: Yale
- Professor of Medicine and Urology at Yale.
- Principal investigator or co-principal investigator on several SWOG clinical trials for genitourinary cancers.
- Authored more than 100 peer-reviewed articles on prostate and bladder cancer research
Interview GoalWe will discuss the current treatment landscape for mCRPC, including the lack of supply for Pluvicto, and the need for another PSMA targeting radiotherapeutic
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
